Comprising more than 60% of all therapeutic targets, G-protein coupled receptor and kinase targets are arguably the most exciting proteins in pharmacology today. Yet, despite massive investment spanning decades, translating early research to clinical success remains frustratingly slow. New approaches are needed that acknowledge and integrate structural, functional and systems components, to accelerate time-to-market.
By attending Visiongain`s GPCR and Kinase Targets conference, you will engage with leading decision makers and thought leaders, enabling you to:
Improve the efficacy of assays to enhance 7 transmembrane and kinase drug discovery
Incorporate improved computational models to evaluate drug-receptor interactions and allosteric modulation of downstream signalling pathways
Evaluate gene splicing for μ-opiod drug development
Target chemogenomic, Wnt and aneuploid-specific pathways for cancer therapy
Employ more accurate siRNA screens to map signalling networks
Dissect variability in chemotherapy through systems pharmacology
Utilise developments in HTS technology to improve patient stratification
Employ alternatives to mass spectrometry when undertaking research
Integrate cell-signalling and systems biology insights into treatments for complex diseases
Selectively activate and quantify beta-arrestin biased ligands for analgesia and heart disease
Better modulate parathyroid hormone release to treat osteoporosis
Assess pharmacotherapies in clinical development for pulmonary, neurodevelopmental and antipsychotic diseases
